News stories about OpGen (NASDAQ:OPGN) have been trending somewhat positive on Wednesday, Accern Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. OpGen earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 46.246936686168 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:

Several analysts have issued reports on the stock. Zacks Investment Research downgraded shares of OpGen from a “buy” rating to a “hold” rating in a research note on Saturday, August 26th. HC Wainwright set a $1.00 price target on shares of OpGen and gave the company a “buy” rating in a research note on Wednesday, August 9th.

Shares of OpGen (NASDAQ:OPGN) opened at $0.27 on Wednesday. The company has a debt-to-equity ratio of -0.55, a quick ratio of 0.19 and a current ratio of 0.29. OpGen has a 12 month low of $0.21 and a 12 month high of $3.10.

ILLEGAL ACTIVITY NOTICE: This article was originally published by Watch List News and is the property of of Watch List News. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at

About OpGen

OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.

Insider Buying and Selling by Quarter for OpGen (NASDAQ:OPGN)

Receive News & Ratings for OpGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.